Omidubicel
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Omidubicel, sold under the brand name Omisirge, is a blood-based cell therapy used for the treatment of blood cancers, and severe aplastic anemia. Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. The most common adverse reactions include infections, graft-versus-host disease, and infusion reactions. Omidubicel is composed of human allogeneic stem cells from umbilical cord blood that are processed and cultured with nicotinamide (a form of vitamin B3). Each dose is patient-specific, containing healthy stem cells from an allogeneic pre-screened donor, meaning it comes from a different individual rather than using the patient's own cells. Omidubicel was approved for medical use in the United States in April 2023.
Omidubicel, sold under the brand name Omisirge, is a blood-based cell therapy used for the treatment of blood cancers, and severe aplastic anemia. Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. The most common adverse reactions include infections, graft-versus-host disease, and infusion reactions. Omidubicel is composed of human allogeneic stem cells from umbilical cord blood that are processed and cultured with nicotinamide (a form of vitamin B3). Each dose is patient-specific, containing healthy stem cells from an allogeneic pre-screened donor, meaning it comes from a different individual rather than using the patient's own cells. Omidubicel was approved for medical use in the United States in April 2023.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1333668220 under CC BY-SA 4.0; modifications have been made.